PTAB Invalidates Patent For Hypertension Treatment
The Patent Trial and Appeal Board on Friday ruled against United Therapeutics Corp. in a challenge to a patent it owns for Remodulin and other pulmonary arterial hypertension treatments, finding that...To view the full article, register now.
Already a subscriber? Click here to view full article